PTGX - Protagonist Therapeutics

-

$undefined

N/A

(N/A)

Protagonist Therapeutics NasdaqGM:PTGX Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Location: 7707 Gateway Boulevard, Newark, CA, 94560, United States | Website: https://www.protagonist-inc.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.386B

Cash

574.4M

Avg Qtr Burn

N/A

Short % of Float

11.45%

Insider Ownership

1.14%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Rusfertide (PTG-300) Details
Blood cancer, Polycythemia vera, Cancer

Phase 3

Update

Phase 2b

Update

PN-943 (α4β7-Integrin Antagonist) Details
Inflammatory bowel disease, Inflammatory disease

Failed

Discontinued

PTG-200 (IL-23R Antagonist) Details
Crohns disease, Inflammatory bowel disease, Inflammatory disease

Failed

Discontinued

Rusfertide (PTG-300) (Hepcidin Mimetic) Details
Genetic disorder, Rare genetic disease

Failed

Discontinued